MedTrace Logo

AHCC® as Immune Modulator in Cancer Patients Treated With Immunotherapy

NCT07118735 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-08-12

No results posted yet for this study

Summary

This is a prospective, double-blind, randomized, placebo-controlled trial to evaluate whether AHCC® (Active Hexose Correlated Compound) can enhance the effect of immunotherapy in liver cancer patients.

Conditions

Interventions

DIETARY_SUPPLEMENT

A standardized extract of cultured Lentinula edodes mycelia (AHCC®)

3 grams of AHCC® taken orally once daily for 6 months or until disease progression or intolerance

DIETARY_SUPPLEMENT

Placebo

3 grams of dextrin (placebo) taken orally once daily for 6 months or until disease progression or intolerance

Sponsors & Collaborators

  • National Cheng-Kung University Hospital

    lead OTHER

Principal Investigators

  • Yih-Jyh Lin · National Cheng Kung University Hospital (NCKUH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-20
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07118735 on ClinicalTrials.gov